ClinicalTrials.gg
CompletedNCT06604442Updated Jul 13, 2026Results posted

Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy

A Phase 4 interventional study of flotufolastat (18F) and piflufolastat (18F) in Prostate Cancer, sponsored by Blue Earth Diagnostics. Completed at 9 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Blue Earth Diagnostics (part of Bracco) · Phase 4, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing flotufolastat F 18 in Prostatic Neoplasms — 6 open to participants now, 7 under way, 2 of them phase 3. flotufolastat F 18 · Prostatic Neoplasms.

Enrollment
9th of 15
62 · median 70
Started
2024
the only one that year
Phase 4
Only one
of the 15
Registered
7th of 15
by date
Lead sponsor
4 of 15
Blue Earth Diagnostics

Among the 15 studies testing flotufolastat F 18 in Prostatic Neoplasms, this one is the 9th largest by enrollment, is the only one that started in 2024, is the only one in phase 4, and was the 7th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 15 studies testing flotufolastat F 18 in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About flotufolastat F 18

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing flotufolastat F 18 in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men with Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy

Read the detailed description

This is a multi-center, prospective intra-patient comparator study of urinary radioactivity (standardized uptake values [SUV]) following both piflufolastat (18F) and flotufolastat (18F) positron emission tomography (PET) in patients with low prostate-specific antigen (PSA; ≤0.5 ng/mL) biochemical recurrence (BCR) of prostate cancer following radical prostatectomy (RP).

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male ≥18 years of age at Visit 1 (Screening).
  • Documented history of localized adenocarcinoma of the prostate with prior curative intent treatment with RP and undetectable PSA post-surgery, experiencing BCR of prostate cancer.
  • At least 6 months must have elapsed after RP.
  • Low PSA BCR defined as PSA ≤0.5 ng/mL.
  • Scheduled by their treating physician to receive a PSMA (18F) PET scan.
  • Written obtained from the patient and ability for the patient to comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  • Patients with any medical condition or circumstance (including receiving an IP) that the investigator believes may compromise the data collected or lead to a failure to fulfill the study requirements.
  • Patients who are planned to have an x-ray contrast agent or any other PET radiotracer within 24 hours prior to either PSMA PET scan.
  • Patients who have already received a piflufolastat (18F) PET scan prior to providing for this study.
  • Patients participating in an interventional clinical trial within 30 days and having received an IP within five biological half-lives prior to either of the PSMA PET scans in this study.
  • Patients with known to the active substance or to any of the of piflufolastat (18F) or flotufolastat (18F).
  • Patients who have previously undergone a cystectomy or have renal failure, or have other conditions that may significantly affect urinary output, as judged by the investigator.
  • Patients who have already received salvage therapy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    piflufolastat (18F) and flotufolastat (18F) positron emission tomography (PET)

    Each patient will be administered a single dose of piflufolastat (18F) on Day 1, followed by a PET scan. At least 24 hours after the piflufolastat (18F) scan, but within 10 calendar days, all patients will be administered a single dose of flotufolastat (18F) followed by a PET scan.

    Drug: flotufolastat (18F) · Drug: piflufolastat (18F)

Interventions

06

What researchers measure

Primary outcomes

  1. To Compare Urinary Bladder Radioactivity Observed on Piflufolastat (18F) PET and Flotufolastat (18F) PET.

    Difference in urinary bladder mean SUV (SUVmean) between piflufolastat (18F) and flotufolastat (18F). A positive difference represents a lower bladder SUVmean for flotufolastat (18F) compared to piflufolastat (18F).

    Time frame: piflufolastat (18F) administration and PET on Day 1; and flotufolastat (18F) administration and PET at least 24 hours after the piflufolastat (18F) scan but within 10 calendar days

Secondary outcomes

  1. Patient Level Detection Rates Following Piflufolastat (18F) PET and Flotufolastat (18F) PET

    Defined as the total number of patients with at least one PET positive lesion / total number of patients.

    Time frame: piflufolastat (18F) administration and PET on Day 1; and flotufolastat (18F) administration and PET at least 24 hours after the piflufolastat (18F) scan but within 10 calendar days

  2. Patient Level Detection Rates Stratified by PSA Level Following Piflufolastat (18F) PET and Flotufolastat (18F) PET

    Defined as the total number of patients with at least one PET positive lesion / total number of patients in PSA group.

    Time frame: Screening, piflufolastat (18F) administration and PET on Day 1; and flotufolastat (18F) administration and PET at least 24 hours after the piflufolastat (18F) scan but within 10 calendar days

  3. Detection Rate for Prostate Bed and Local Recurrences by Subregion Following for Piflufolastat (18F) PET and Flotufolastat (18F) PET

    Time frame: Screening, piflufolastat (18F) administration and PET on Day 1; and flotufolastat (18F) administration and PET at least 24 hours after the piflufolastat (18F) scan but within 10 calendar days

  4. Detection Rate for Pelvic Lymph Node (PLN) Following for Piflufolastat (18F) PET and Flotufolastat (18F) PET

    Time frame: Piflufolastat (18F) administration and PET on Day 1; and flotufolastat (18F) administration and PET at least 24 hours after the piflufolastat (18F) scan but within 10 calendar days

07

Results

Posted May 12, 2026

Participant flow

Participant flow — Overall Study
MilestonePiflufolastat (18F) and Flotufolastat (18F) Positron Emission Tomography (PET)
Started62
Completed55
Not completed7

Outcome measures

PrimaryTo Compare Urinary Bladder Radioactivity Observed on Piflufolastat (18F) PET and Flotufolastat (18F) PET.

Difference in urinary bladder mean SUV (SUVmean) between piflufolastat (18F) and flotufolastat (18F). A positive difference represents a lower bladder SUVmean for flotufolastat (18F) compared to piflufolastat (18F).

Time frame:
piflufolastat (18F) administration and PET on Day 1; and flotufolastat (18F) administration and PET at least 24 hours after the piflufolastat (18F) scan but within 10 calendar days
Reported as:
Median · ratio
To Compare Urinary Bladder Radioactivity Observed on Piflufolastat (18F) PET and Flotufolastat (18F) PET.
ratioPiflufolastat (18F) PETFlotufolastat (18F) PET
To Compare Urinary Bladder Radioactivity Observed on Piflufolastat (18F) PET and Flotufolastat (18F) PET.29.0 (18.9 to 40.8)10.9 (6.0 to 18.5)
Statistical analysis
  • Piflufolastat (18F) PET vs Flotufolastat (18F) PET · Wilcoxon (Mann-Whitney) · p = <0.001 · Median difference (final values): 15.1IQR 8.5, 27.0
SecondaryPatient Level Detection Rates Following Piflufolastat (18F) PET and Flotufolastat (18F) PET

Defined as the total number of patients with at least one PET positive lesion / total number of patients.

Time frame:
piflufolastat (18F) administration and PET on Day 1; and flotufolastat (18F) administration and PET at least 24 hours after the piflufolastat (18F) scan but within 10 calendar days
Reported as:
Number · percentage of participants
Patient Level Detection Rates Following Piflufolastat (18F) PET and Flotufolastat (18F) PET
percentage of participantsPiflufolastat (18F) PETFlotufolastat (18F) PET
Patient Level Detection Rates Following Piflufolastat (18F) PET and Flotufolastat (18F) PET27.3 (16.1 to 41.0)45.5 (32.0 to 59.4)
SecondaryPatient Level Detection Rates Stratified by PSA Level Following Piflufolastat (18F) PET and Flotufolastat (18F) PET

Defined as the total number of patients with at least one PET positive lesion / total number of patients in PSA group.

Time frame:
Screening, piflufolastat (18F) administration and PET on Day 1; and flotufolastat (18F) administration and PET at least 24 hours after the piflufolastat (18F) scan but within 10 calendar days
Reported as:
Number · percentage of participants
Patient Level Detection Rates Stratified by PSA Level Following Piflufolastat (18F) PET and Flotufolastat (18F) PET
percentage of participantsFlotufolastat (18F) PET; PSA ≤ 0.2 ng/mLPiflufolastat (18F) PET; PSA ≤ 0.2 ng/mLFlotufolastat (18F) PET; PSA > 0.2 ng/mLPiflufolastat (18F) PET; PSA > 0.2 ng/mL
Patient Level Detection Rates Stratified by PSA Level Following Piflufolastat (18F) PET and Flotufolastat (18F) PET52.4 (29.8 to 74.3)38.1 (18.1 to 61.6)41.2 (24.6 to 59.3)20.6 (8.7 to 37.9)
SecondaryDetection Rate for Prostate Bed and Local Recurrences by Subregion Following for Piflufolastat (18F) PET and Flotufolastat (18F) PET
Time frame:
Screening, piflufolastat (18F) administration and PET on Day 1; and flotufolastat (18F) administration and PET at least 24 hours after the piflufolastat (18F) scan but within 10 calendar days
Reported as:
Number · percentage of participants
Detection Rate for Prostate Bed and Local Recurrences by Subregion Following for Piflufolastat (18F) PET and Flotufolastat (18F) PET
percentage of participantsFlotufolastat (18F) Positron Emission Tomography (PET)Piflufolastat (18F) PET
Prostate Bed18.2 (9.1 to 30.9)10.9 (4.1 to 22.2)
Remnant Seminal Vesicles/Lateral Surgical Margin7.3 (2.0 to 17.6)3.6 (0.4 to 12.5)
Retrovesical3.6 (0.4 to 12.5)3.6 (0.4 to 12.5)
Vesicourethral Anastomosis7.3 (2.0 to 17.6)1.8 (0.0 to 9.7)
SecondaryDetection Rate for Pelvic Lymph Node (PLN) Following for Piflufolastat (18F) PET and Flotufolastat (18F) PET
Time frame:
Piflufolastat (18F) administration and PET on Day 1; and flotufolastat (18F) administration and PET at least 24 hours after the piflufolastat (18F) scan but within 10 calendar days
Reported as:
Number · percentage of participants
Detection Rate for Pelvic Lymph Node (PLN) Following for Piflufolastat (18F) PET and Flotufolastat (18F) PET
percentage of participantsFlotufolastat (18F) Positron Emission Tomography (PET)Piflufolastat (18F) PET
Detection Rate for Pelvic Lymph Node (PLN) Following for Piflufolastat (18F) PET and Flotufolastat (18F) PET16.4 (7.8 to 28.8)14.5 (6.5 to 26.7)

Adverse events

Collected over Adverse events were collected up to 10 days following administration of piflufolastat (18F) and up to 24 hours post administration of flotufolastat (18F). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Piflufolastat (18F) PET0/62 (0%)1/62 (1.6%)3/62 (4.8%)
Flotufolastat (18F) PET0/57 (0%)0/57 (0%)2/57 (3.5%)
Most frequent serious events
Most frequent serious events
EventPiflufolastat (18F) PETFlotufolastat (18F) PET
Extortional dyspnoeaRespiratory, thoracic and mediastinal disorders1/620/57
Most frequent other events
Most frequent other events
EventPiflufolastat (18F) PETFlotufolastat (18F) PET
Abdominal DiscomfortGastrointestinal disorders0/621/57
DiarrheaGastrointestinal disorders1/621/57
Taste DisorderNervous system disorders0/621/57
FatigueGeneral disorders1/620/57
Dyspnoea exertionalRespiratory, thoracic and mediastinal disorders1/620/57
FlushingVascular disorders1/620/57

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Piflufolastat (18F) and Flotufolastat (18F) Positron Emission Tomography (PET)
<=18 years0
Between 18 and 65 years15
>=65 years40
Sex: Female, Male
Sex: Female, Male(Participants)Piflufolastat (18F) and Flotufolastat (18F) Positron Emission Tomography (PET)
Female0
Male55
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Piflufolastat (18F) and Flotufolastat (18F) Positron Emission Tomography (PET)
Hispanic or Latino5
Not Hispanic or Latino50
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Piflufolastat (18F) and Flotufolastat (18F) Positron Emission Tomography (PET)
Race — White44
Race — Black or African American4
Race — Asian3
Race — Not Reported1
Race — Unknown2
Race — Other1
Baseline Weight
Baseline Weight(kg)Piflufolastat (18F) and Flotufolastat (18F) Positron Emission Tomography (PET)
Mean90.0 ± 16.60
Baseline Height
Baseline Height(cm)Piflufolastat (18F) and Flotufolastat (18F) Positron Emission Tomography (PET)
Mean177.3 ± 7.70
Baseline Body Mass Index (kg/m2)
Baseline Body Mass Index (kg/m2)(Kg/m2)Piflufolastat (18F) and Flotufolastat (18F) Positron Emission Tomography (PET)
Mean28.6 ± 4.66
08

Study locations

9 sites
  • Mayo Clinic
    Phoenix, Arizona 85054, United States
  • City of Hope Medical Center
    Duarte, California 91010, United States
  • Tower Urology
    Los Angeles, California 90048, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • Endeavor Health- Glenbrook Hospital
    Glenview, Illinois 60026, United States
  • XCancer Omaha/Urology Cancer Center
    Omaha, Nebraska 68130, United States
  • Montefiore Medical Center
    The Bronx, New York 10461, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Urology San Antonio
    San Antonio, Texas 78229, United States
09

References and documents

Publications

  • Nordquist LT, Andrews JR, Kuo PH, Gartrell BA, Josephson D, Purysko AS, Saltzstein DR, Pathak RA, Shore N, Sykes J, Penny R, Davis P, Helfand BT. An intra-patient contemporaneous comparison of 18F-piflufolastat and 18F-flotufolastat urinary radioactivity and pelvic region detection rates in men with low PSA biochemical recurrence of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2026 May;53(6):3529-3541. doi: 10.1007/s00259-025-07732-y. Epub 2026 Feb 23. PubMed 41729277 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Aug 2025, 8 months.

Results were first posted in May 2026, 8 months after primary completion.

Of 52 phase 4 interventional studies under Prostatic Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2024
First posted
Sep 19, 2024
StartActual
Dec 4, 2024
Primary completionActual
Aug 29, 2025
CompletionActual
Aug 29, 2025
Results first posted
May 12, 2026
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06604442
Collaborators
Aixial Group
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Dec 4, 2024
Primary completion
Aug 29, 2025
Completion
Aug 29, 2025
Results posted
May 12, 2026
Last update
Jul 13, 2026

Study contacts

Brian Helfand, M.D.
principal investigator · Endeavor Health NorthShore Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Flotufolastat F 18 · Piflufolastat

Start the discussion